In a phase-I study of a monoclonal antibody (KHK2866) against HB-EGF, neurotoxicity manifested as complex partial seizures, aphasia, and confusion after first-dose intravenous administration, but these AEs were reversible and unpredictable [23, 25]. Here, EGF is linked to Aphasia.